For more than a century, one of medicine’s greatest achievements has also highlighted one of its greatest unfinished challenges: insulin can keep millions of people with diabetes alive, but it does not eliminate the underlying disease. Now, pioneering research from China is pushing diabetes treatment toward an entirely different possibility, restoring the body’s own ability to produce insulin using stem-cell-derived pancreatic islet cells. In landmark clinical cases, Chinese scientists have transformed patients’ own cells into insulin-producing cells and transplanted them back into the body, enabling individual patients with Type 1 diabetes and Type 2 diabetes to become insulin-independent. The results represent an extraordinary advance in regenerative medicine, but viral claims that China has already “reversed” or “cured” Type 1 and Type 2 diabetes for everyone go considerably beyond the scientific evidence. What researchers have demonstrated so far is potentially more important than a sensational headline: proof in a very small number of patients that damaged or lost insulin-producing capacity can, under certain circumstances, be biologically restored.
The breakthrough addresses the biological machinery at the centre of diabetes. Insulin, produced by beta cells within pancreatic islets, enables glucose circulating in the blood to enter cells and be used or stored for energy. In Type 1 diabetes, the immune system destroys insulin-producing beta cells, leaving patients dependent on externally supplied insulin. Type 2 diabetes is different: it typically begins with insulin resistance, in which the body does not respond effectively to insulin, and can progress to deterioration of pancreatic beta-cell function. More than 30% of people with Type 2 diabetes eventually require external insulin, according to the researchers behind one of the Chinese studies. Conventional treatments, including insulin injections, glucose-lowering medicines, continuous glucose monitors, insulin pumps, dietary management and exercise—can dramatically improve outcomes, but they generally manage diabetes rather than reconstruct the cellular system responsible for producing insulin. Stem-cell-derived islet therapy attempts something fundamentally different: replace or regenerate functional insulin-producing cells so that the body can once again regulate blood glucose biologically.
One of the most significant advances came from a Chinese research team whose findings were published in the prestigious journal Cell in 2024. Scientists treated a 25-year-old woman with Type 1 diabetes using chemically induced pluripotent stem-cell-derived islets created from her own cells. The researchers reprogrammed adult cells into a pluripotent state, giving them the capacity to develop into specialised cell types, and then guided them into functional pancreatic islet cells capable of producing insulin in response to glucose. These laboratory-grown islets were transplanted beneath tissue in the abdominal region. Approximately 75 days after transplantation, the patient achieved sustained insulin independence, meaning she no longer required external insulin to control her blood glucose. The peer-reviewed study described the case as the first reported autologous transplantation of this type of chemically induced pluripotent stem-cell-derived islet therapy in a patient with Type 1 diabetes.
The scientific importance of the case goes far beyond eliminating insulin injections for one patient. Type 1 diabetes presents two enormous biological problems: replacing the beta cells destroyed by disease and preventing the immune system from destroying replacement cells. Traditional pancreatic islet transplantation has already demonstrated that replacing functional islets can restore insulin production in some patients, but the approach is constrained by the scarcity of donor organs and often by the need for long-term immunosuppressive medication. Stem cells potentially change the supply equation. Instead of depending entirely on deceased organ donors, scientists could theoretically manufacture large quantities of insulin-producing cells in laboratories. Using cells derived from a patient’s own body may also offer advantages in reducing some forms of immune incompatibility, although Type 1 diabetes remains particularly challenging because the underlying autoimmune process can still threaten newly introduced beta cells. Researchers are consequently exploring immune protection, encapsulation and gene-editing strategies designed to allow transplanted cells to survive without lifelong systemic immunosuppression.
China has also produced important evidence involving Type 2 diabetes. In another landmark study published in Cell Discovery, researchers treated a 59-year-old man who had lived with Type 2 diabetes for approximately 25 years and had severely impaired pancreatic islet function. Scientists generated insulin-producing islet tissue through cellular reprogramming and transplantation. The patient was subsequently able to discontinue insulin, demonstrating that regenerative cell therapy may potentially restore meaningful insulin-producing capacity even after long-standing Type 2 diabetes in carefully selected circumstances. The study was particularly significant because Type 2 diabetes affects a vastly larger global population than Type 1 and is biologically more complex than simply replacing missing insulin. Insulin resistance, obesity, genetics, metabolic health and progressive beta-cell dysfunction can all contribute to the disease, meaning cell replacement alone is unlikely to represent a universal solution for every patient. Nevertheless, restoring functional beta-cell capacity could eventually become transformative for selected people with advanced disease and severe loss of pancreatic function.
Taken together, the Chinese Type 1 and Type 2 diabetes cases mark an important transition in medicine: from managing a biological deficiency to attempting to rebuild the biological system itself. For decades, diabetes innovation has largely focused on making disease management safer and more precise, better insulin formulations, smaller needles, continuous glucose monitoring, automated insulin delivery, smarter pumps, mobile health platforms and artificial pancreas systems. These technologies have saved lives and dramatically improved quality of life, and they will remain essential. Regenerative medicine introduces a different ambition. Instead of asking how technology can continuously compensate for a pancreas that no longer produces sufficient insulin, researchers are asking whether medicine can create new functional insulin-producing cells and return part of that biological responsibility to the body. If successfully scaled, this could represent one of the most important paradigm shifts in diabetes treatment since the discovery of insulin in 1921.
The word “cure,” however, requires caution. These breakthroughs do not mean that hospitals in China or elsewhere can currently offer a proven universal stem cell cure for Type 1 or Type 2 diabetes. The strongest early results involve individual patients or very small experimental studies, and larger clinical trials with longer follow-up are required to establish durability, safety, reproducibility, appropriate patient selection and long-term risks. Researchers still need to determine whether transplanted cells continue functioning effectively for many years, whether immune attack can be reliably prevented, whether abnormal cell growth or tumour formation can be avoided, how manufacturing can be standardised and whether treatments can be delivered affordably at population scale. A 2025 review of stem cell therapies for diabetes highlighted continuing challenges including safety, transplantation efficiency and immune rejection, while a 2026 review concluded that stem-cell-derived beta-cell therapy has transformative curative potential but still requires substantial research before widespread clinical application.
There is another crucial distinction between insulin independence, remission, functional cure and permanent biological cure. A patient who no longer needs insulin after an experimental transplant has achieved an extraordinary clinical outcome, but that does not automatically prove that the original disease mechanism has permanently disappeared. In Type 1 diabetes, the autoimmune process that destroyed the original beta cells remains a central challenge. Some transplant recipients may require immunosuppressive treatment, particularly where transplantation occurs in patients already taking such drugs for another organ transplant. In Type 2 diabetes, eliminating insulin injections does not necessarily eliminate the metabolic drivers of disease. Weight, insulin resistance, diet, physical activity, genetics and other health conditions can continue to influence glucose regulation. Scientific precision therefore matters: the Chinese results demonstrate compelling evidence of restored endogenous insulin production and insulin independence in landmark patients, not yet a universally available cure for diabetes.
The economic implications could eventually be enormous. Diabetes is not merely a medical condition; it is one of the world’s largest chronic-disease burdens, generating lifelong expenditure on medicines, insulin, glucose-monitoring equipment, consultations, hospitalisation and treatment for complications involving the kidneys, cardiovascular system, nerves, eyes and limbs. A durable regenerative therapy capable of restoring insulin production could fundamentally change the lifetime economics of diabetes care. Healthcare systems would have to compare a potentially expensive one-time or limited-course cell therapy against decades of insulin, medicines, monitoring technologies and treatment of complications. Pharmaceutical companies, biotechnology firms, insurers and governments would face an entirely new health-economic equation: what is the value of restoring biological function compared with financing lifelong disease management? The answer will depend heavily on how durable these therapies prove to be and whether advanced cell manufacturing can eventually be industrialised at affordable cost.
China’s role in these developments also reflects the accelerating global competition in biotechnology, regenerative medicine, cell therapy and gene editing. The country has invested heavily in scientific research, biomedical infrastructure, advanced manufacturing and translational medicine, enabling research teams to move increasingly sophisticated technologies from laboratories toward human clinical testing. Yet China is not alone in the race. Researchers and biotechnology companies across the United States, Europe, Canada and other markets are developing stem-cell-derived pancreatic islet therapies, encapsulation systems and genetically engineered cells designed to evade immune destruction. The global scientific objective is converging around a powerful idea: create a renewable source of functional beta cells, transplant them safely and protect them long enough to provide reliable glucose-responsive insulin production. Research published through 2025 and 2026 shows that the field is progressing rapidly, including work on gene-edited cells designed to reduce immune recognition.
For Africa, the breakthrough raises both extraordinary hope and an uncomfortable question about access. Advanced therapies often reach wealthy health systems years before they become accessible in lower-income countries. Diabetes is rising across African populations while many patients still struggle to access basic diagnosis, regular glucose monitoring, affordable insulin and continuous clinical care. A future in which regenerative medicine can restore insulin production but remains financially or geographically inaccessible to most patients would create another layer of global health inequality. African governments, universities, hospitals, regulators and private-sector investors therefore need to participate early in emerging fields such as regenerative medicine rather than waiting until technologies mature elsewhere. Building biomedical research capacity, strengthening clinical-trial infrastructure, training specialists, improving laboratories, developing ethical and regulatory frameworks and establishing international research partnerships could determine whether Africa becomes merely a consumer of next-generation medicine or an active participant in developing and deploying it.
Digital health will also remain central even if regenerative therapies eventually become mainstream. Patients receiving stem-cell-derived islet transplants will still require sophisticated monitoring, especially during early treatment and long-term follow-up. Continuous glucose monitoring, remote consultations, electronic health records, artificial intelligence, laboratory integration and personalised data analytics could help clinicians measure whether transplanted cells are functioning effectively and detect complications earlier. In countries where specialists are concentrated in major cities, telemedicine and digitally connected care models could extend follow-up beyond specialist hospitals. The future of diabetes care may therefore not involve regenerative medicine replacing digital health, but rather the convergence of biotechnology, artificial intelligence, connected diagnostics, precision medicine and financial innovation into a more integrated model of chronic-disease care.
Financial inclusion is equally relevant because a medical breakthrough has limited social value if patients cannot afford to access it. Cell therapies can initially be extremely expensive because they require specialised laboratories, advanced manufacturing, quality control, transplantation expertise and long-term monitoring. If stem-cell-derived diabetes treatments eventually become approved at scale, governments and health systems will need innovative financing mechanisms, including insurance, national health coverage, outcome-based financing and potentially new public-private models, to prevent access from becoming determined entirely by personal wealth. The greatest measure of success will not simply be whether science can make insulin-producing cells in a laboratory, but whether health systems can eventually make safe and effective therapies available to ordinary people.
The Chinese breakthroughs therefore represent something both historic and unfinished. Scientists have shown in landmark human cases that stem-cell-derived islet cells can restore the body’s ability to produce insulin strongly enough for individual patients with Type 1 and Type 2 diabetes to stop relying on external insulin. That achievement would have sounded closer to science fiction only a generation ago. Yet the journey from exceptional experimental success to safe, affordable and universally accessible treatment is long. Larger trials, longer follow-up, immune protection, manufacturing scale, regulatory approval, affordability and equitable access remain major hurdles. The evidence justifies genuine optimism, but not claims that diabetes has already been universally cured.
What makes this moment extraordinary is the direction in which medicine is moving. For more than 100 years, insulin transformed diabetes from an almost certain death sentence, particularly for people with Type 1 diabetes, into a condition that millions can manage. The next frontier is more ambitious: not merely supplying the insulin the body cannot produce, but rebuilding the cellular machinery capable of producing it naturally. China’s pioneering stem cell research has provided some of the strongest human evidence yet that this future may be biologically possible. The question is no longer simply whether scientists can create insulin-producing cells from stem cells. They have. The defining questions now are whether those cells can work safely for decades, survive immune attack, be manufactured for millions of people and become affordable enough to transform diabetes care not only for a handful of pioneering patients, but for the world.
